Experimental cognition-related small molecule · Fact sheet
Unifiram
Also known as DM232
Unifiram is an experimental small molecule investigated in animal memory models. Those experiments do not establish a safe or effective human cognitive-enhancement treatment.
What is Unifiram?
Unifiram and sunifiram have related research histories but are different molecules.
Enantiomer-specific experiments cannot automatically describe every preparation.
Benefits & claims
Readers encounter Unifiram in discussions of cognition, mood or mental fatigue. The relevant study population and outcome determine whether those claims are supported.
What the evidence supports
- AMPA-related signaling was implicated in animal anti-amnesia experiments.
- Chemical structure and enantiomer studies explore activity rather than demonstrating human outcomes.
- No human dose can be inferred from these animal experiments.
Research areas
- Cognition and memory
- Neurologic or psychiatric research
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Unifiram. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Unifiram and sunifiram have related research histories but are different molecules.
Formulation differences
- Enantiomer-specific experiments cannot automatically describe every preparation.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Side effects & risks
- Human neurologic adverse effects, interactions and chronic safety have not been characterized adequately.
- Increased excitatory activity is a biological effect requiring safety assessment, not a guarantee of improved cognition.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceThe cited studies concern preclinical pharmacology, chemical analogs and stereochemistry. There is no verified human efficacy regimen in these sources.
Studies
Animal AMPA-related experiments.
Structure–activity experiments on DM232 and DM235.
Enantiomer synthesis and preliminary animal pharmacology.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Unifiram is not an FDA-approved treatment for the cognitive or mood uses discussed here. Regional use, historical trials and online availability are separate from U.S. drug approval.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram).
- Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs.
- Enantioselective synthesis and preliminary pharmacological evaluation of the enantiomers of unifiram (DM232), a potent cognition-enhancing agent.
Open questions
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Summary
No human dose can be inferred from these animal experiments.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedAMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram).
Animal AMPA-related experiments.
- pubmedStructure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs.
Structure–activity experiments on DM232 and DM235.
- pubmedEnantioselective synthesis and preliminary pharmacological evaluation of the enantiomers of unifiram (DM232), a potent cognition-enhancing agent.
Enantiomer synthesis and preliminary animal pharmacology.